Review of: "Comparing Visual and Software-Based Quantitative Assessment Scores of Lung Parenchymal Involvement Quantification in COVID-19 Patients"

Anisha Isaac

Potential competing interests: No potential competing interests to declare.

1. The authors did a good work in comparing Visual and Software-Based Quantitative Assessment Scores of Lung Parenchymal Involvement Quantification. However, it would be advisable for the writers to provide a comprehensive and in-depth report of the working of software. To be specific, there is insufficient information provided on how AI software works under **Software-based quantitative assessment score.**

2. I'd also recommend the authors to provide the justification and advantage behind selecting these two particular AI software (Icolung and Philips IntelliSpace Portal clinical application CT-COPD) to assess the score?

3. **Could you please explain which metrics and how they are compared between the results of the Inter-Reader Agreement of the Visual and Software-Based CT Assessment?**